BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 506 filers reported holding BIO-TECHNE CORP in Q2 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $5,935 | -10.5% | 80 | 0.0% | 0.00% | -25.0% |
Q4 2022 | $6,630 | +10.5% | 80 | +300.0% | 0.00% | 0.0% |
Q3 2022 | $6,000 | -25.0% | 20 | 0.0% | 0.00% | -20.0% |
Q2 2022 | $8,000 | 0.0% | 20 | 0.0% | 0.01% | 0.0% |
Q1 2022 | $8,000 | -20.0% | 20 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $10,000 | 0.0% | 20 | 0.0% | 0.01% | 0.0% |
Q3 2021 | $10,000 | +11.1% | 20 | 0.0% | 0.01% | -58.3% |
Q2 2021 | $9,000 | +12.5% | 20 | 0.0% | 0.01% | -33.3% |
Q1 2021 | $8,000 | +33.3% | 20 | 0.0% | 0.02% | +200.0% |
Q4 2020 | $6,000 | +20.0% | 20 | 0.0% | 0.01% | -57.1% |
Q3 2020 | $5,000 | -99.9% | 20 | 0.0% | 0.01% | +250.0% |
Q2 2020 | $5,281,000 | +39.3% | 20 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $3,792,000 | +28.2% | 20 | 0.0% | 0.00% | +100.0% |
Q4 2019 | $2,959,000 | -24.4% | 20 | 0.0% | 0.00% | -33.3% |
Q3 2019 | $3,913,000 | -6.2% | 20 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $4,170,000 | +5.0% | 20 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $3,971,000 | +37.2% | 20 | 0.0% | 0.00% | +50.0% |
Q4 2018 | $2,894,000 | -29.1% | 20 | 0.0% | 0.00% | -33.3% |
Q3 2018 | $4,082,000 | +38.0% | 20 | 0.0% | 0.00% | +50.0% |
Q2 2018 | $2,959,000 | -40.6% | 20 | -39.4% | 0.00% | -50.0% |
Q1 2018 | $4,984,000 | – | 33 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |